# PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

> **NCT03650348** · PHASE1 · COMPLETED · sponsor: **Pieris Pharmaceuticals, Inc.** · enrollment: 41 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER2-positive Bladder Cancer
- HER2-positive Solid Tumor

## Interventions

- **DRUG:** PRS-343 in Combination with Atezolizumab

## Key facts

- **NCT ID:** NCT03650348
- **Lead sponsor:** Pieris Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-21
- **Primary completion:** 2022-08-11
- **Final completion:** 2022-08-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03650348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03650348, "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03650348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*